Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05848843 2024-01-23

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Phase 1 Withdrawn

Thoracic

Lung Neoplasms

NCT02793466 2023-09-22

Durvalumab in Pediatric and Adolescent Patients

Phase 1 Completed

15 enrolled

CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT03452332 2023-09-13

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Phase 1 Completed

20 enrolled

Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase 1 Terminated

1 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03275597 2023-05-15

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Phase 1 Terminated

17 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Phase 1 Completed

27 enrolled

Thoracic

High-Risk Resectable NSCLC

NCT01975831 2022-10-12

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1 Completed

104 enrolled 23 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Phase 1 Terminated

6 enrolled 11 charts

Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

NCT03773666 2022-09-13

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Phase 1 Completed

12 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03122496 2022-06-08

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Phase 1 Completed

13 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT03799744 2022-03-28

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Phase 1 Unknown

20 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT05157542 2021-12-15

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Phase 1 Unknown

9 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

RESOLVE

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

NOVOCURE

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

CONCORDE

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

TRAMUNE

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

iRE-C

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Induction

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

PREDICT

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Durvalumab in Pediatric and Adolescent Patients

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC